A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Hematologic precursor conditions include monoclonal gammopathy of undetermined significance (MGUS), monoclonal B-cell lymphocytosis (MBL), and clonal hematopoiesis (CH). These conditions are ...
Liquid biopsy technologies, particularly circulating tumor DNA, or ctDNA, are changing how clinicians monitor hematologic malignancies. In this interview, Dr. Oksana Fabri explains how ctDNA provides ...
INCA033989 targets mutCALR in ET patients with Type 1 CALR mutations, showing promise in early trials with rapid, durable hematological responses and a favorable safety profile. CALR mutations are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results